On June 01, 2016 Portola Pharmaceuticals Inc. (NASDAQ:PTLA), reported that it recently dosed the first patient in a Phase 2a study that is evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell and T-cell malignancies who have failed multiple therapies (Press release, Portola Pharmaceuticals, JUN 1, 2016, View Source [SID:1234512916]). Cerdulatinib is an oral, dual Syk/JAK kinase inhibitor in development to treat patients with resistant or relapsed hematologic cancer. Cerdulatinib inhibits two key cell signaling pathways that promote cancer cell growth in certain hematologic malignancies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Portola recently completed a Phase 1 study of cerdulatinib, which identified the maximum tolerated dose. Pharmacokinetic and pharmacodynamic outcomes data from the Phase 1 study will be presented in a poster session at the upcoming American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting 2016, which is taking place from June 3-7 in Chicago. Final results of the Phase 1 study, as well as data from two other cerdulatinib studies, will be presented in poster and e-poster sessions at the European Hematology Association (EHA) (Free EHA Whitepaper) 21st Annual Congress, which is taking place from June 9-12 in Copenhagen.

The cerdulatinib ASCO (Free ASCO Whitepaper) abstract is available at abstracts.asco.org and the EHA (Free EHA Whitepaper) abstracts are available at http://bit.ly/1U852D2. Details regarding the poster and e-poster presentations, which will include additional data not available in the abstracts, follow.

ASCO Annual Meeting 2016

Abstract Title (abstract #7557/poster board #113): Cerdulatinib (PRT062070): A dual SYK/JAK inhibitor in patients with relapsed/refractory b-cell malignancies — Pharmacokinetic and pharmacodynamic outcomes with twice-daily (BID) vs once-daily (QD) dosing
Presenting Author: Paul A. Hamlin, M.D., medical oncologist, Memorial Sloan Kettering Cancer Center
Poster Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Poster Presentation Date and Time: Monday, June 6, 8:00-11:30 a.m. Central Time
Location: McCormick Place, Hall A
EHA 21st Congress

Abstract Title (abstract #LB2252): Phase 1 final results and Phase 2a dose selection for cerdulatinib (PRT062070), a dual Syk/JAK inhibitor in patients with relapsed/refractory B-cell malignancies
Session Title: Chronic lymphocytic leukemia and related disorders — Clinical
E-poster Presentation Date and Time: Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
E-Poster Location: Bella Center, Hall H

Abstract Title (abstract #E1017): Combined SYK and JAK inhibition by cerdulatinib induces apoptosis in CLL and overcomes resistance to ibrutinib
Session Title: Chronic lymphocytic leukemia and related disorders — Biology
E-poster Presentation Date and Time: Friday, June 10, 9:30 a.m.-Saturday, June 11, 7 p.m. CEST
Location: Bella Center, Hall H

Abstract Title (abstract #P590): The SYK/JAK inhibitor cerdulatinib shows promising in vitro activity in chronic lymphocytic leukemia
Session Title: Genomic complexity in CLL
Poster Presentation Date and Time: Saturday, June 11, 5:30-7:00 p.m. CEST
Location: Poster Area, Hall H